PMID- 23959669
OWN - NLM
STAT- MEDLINE
DCOM- 20140626
LR  - 20140214
IS  - 1898-4002 (Electronic)
IS  - 1896-1126 (Linking)
VI  - 58
IP  - 2
DP  - 2013
TI  - Over-dialysis plasma RANTES increase depends on heparin dose and cardiovascular 
      disease status.
PG  - 311-9
LID - 10.2478/ams-2013-0008 [doi]
AB  - PURPOSE: The lifespan of maintenance hemodialysis patients is reduced mainly 
      because of cardiovascular complications due to accelerated atherosclerosis and 
      impaired angiogenesis. We aimed to compare the effect of unfractionated heparin 
      (UFH) and enoxaparin used as anticoagulants during hemodialysis (HD) on 
      circulating levels of heparin-binding, anti-angiogenic Endostatin, 
      pro-inflammatory RANTES (Regulated upon Activation, Normal T cell Expressed and 
      Secreted), and MCP-1 (Monocyte Chemoattractant Protein-1). METHODS: We enrolled 
      22 chronic HD patients, who were randomly assigned to either enoxaparin (n=11) or 
      UFH (n=11) anticoagulation, and followed prospectively for 12 weeks before 
      crossing over to the alternate therapy for further 12 weeks. The factors were 
      measured (ELISA) at the start, 10 and 180 min of HD, and compared to 20 healthy 
      volunteers. RESULTS: The baseline Endostatin, RANTES, and MCP-1 levels in 
      patients were higher than in controls and comparable during enoxaparin and UFH 
      treatment. RANTES significantly increased during both enoxaparin and UFH 
      anticoagulated HD, while over-HD Endostatin and MCP-1 levels remained stable 
      regardless of the heparin sort. About 25% RANTES increase after 10 min of HD 
      positively correlated with the dose of both heparins and HD duration. The switch 
      from enoxaparin to UFH treatment had no impact on the levels of parameters 
      studied. Patients with ischemic heart disease had less RANTES increase after 180 
      min of HD especially during enoxaparin treatment. CONCLUSION: RANTES is 
      dose-depended and transitory increased in response to both UFH and enoxaparin 
      administration during HD. Cardiovascular disease status occurred to be the most 
      important predictor of its over-HD level.
FAU - Naumnik, B
AU  - Naumnik B
FAU - Koc-Zorawska, E
AU  - Koc-Zorawska E
FAU - Mysliwiec, M
AU  - Mysliwiec M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Adv Med Sci
JT  - Advances in medical sciences
JID - 101276222
RN  - 0 (Anticoagulants)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CCL5)
RN  - 0 (Endostatins)
RN  - 0 (Enoxaparin)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/administration & dosage
MH  - Appointments and Schedules
MH  - Atherosclerosis/*etiology
MH  - Chemokine CCL2/blood
MH  - Chemokine CCL5/*blood
MH  - Dose-Response Relationship, Drug
MH  - Endostatins/blood
MH  - Enoxaparin/*administration & dosage
MH  - Female
MH  - Heparin/*administration & dosage
MH  - Humans
MH  - Kidney Failure, Chronic/*complications/therapy
MH  - Male
MH  - Middle Aged
MH  - Neovascularization, Pathologic/etiology
MH  - Renal Dialysis/*adverse effects/methods
EDAT- 2013/08/21 06:00
MHDA- 2014/06/27 06:00
CRDT- 2013/08/21 06:00
PHST- 2013/08/21 06:00 [entrez]
PHST- 2013/08/21 06:00 [pubmed]
PHST- 2014/06/27 06:00 [medline]
AID - S1896-1126(14)60205-4 [pii]
AID - 10.2478/ams-2013-0008 [doi]
PST - ppublish
SO  - Adv Med Sci. 2013;58(2):311-9. doi: 10.2478/ams-2013-0008.